A Patient With Schizophrenia in Remission Relapses Following COVID-19: A Case Report.
| Autor: | Shaaban SS; Department of Medicine, King Abdulaziz University, Jeddah, SAU., Bhullar R; Department of Psychiatry and Behavioral Sciences, Dayanand Medical College and Hospital, Ludhiana, IND., Mohammad I; Department of Psychiatry, Hawler Psychiatric Hospital, Erbil, IRQ., Hashmi A; Department of Behavioral Health, Westpark Springs, Houston, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Oct 02; Vol. 14 (10), pp. e29845. Date of Electronic Publication: 2022 Oct 02 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.29845 |
| Abstrakt: | As managing COVID-19 complications has become more prevalent in psychiatry, its effects can range from provoking new illnesses in previously healthy individuals to inducing relapses in patients in remission. However, an aspect of COVID-19's influence that is not well documented is its effect on medication responsiveness. In this case, we present a 28-year-old male diagnosed with treatment-resistant schizophrenia for eight years. While in remission on a maintenance dose of clozapine, he was admitted to the hospital with signs of severe psychosis after testing positive for COVID-19. On admission, he did not have any other major stressors and no prior comorbidities that could have induced the relapse. Despite being on a higher dose of clozapine for four weeks while hospitalized, the patient's psychosis did not improve. This raises the question if his infection had altered his response to medication that previously brought on remission. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Shaaban et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|